China granted Chongqing Pharscin Pharmaceutical (SHE:002907) drug re-registration approval for three drugs, according to a Tuesday filing with the Shenzhen bourse.
The Ganju Bingmei traditional Chinese tablets are indicated for pharyngitis and loss of voice, while its Liuwei Anshen traditional Chinese capsules are indicated for relief from phlegm and insomnia, the filing said.
Meanwhile, its Cilostazol drug also obtained approval. The drug is indicated for anti-platelet aggregation and dilation of peripheral blood cells, among other effects, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments